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Abstract 
Background: In patients with diffuse large B‑cell lymphoma (DLBCL), central nervous system (CNS) relapse is uncom‑
mon but is nearly always fatal. This study aimed to determine the risk factors for CNS relapse in DLBCL patients and to 
evaluate the efficacy of rituximab and intrathecal chemotherapy prophylaxis for CNS relapse reduction.
Methods: A total of 511 patients with newly diagnosed DLBCL treated at the Sun Yat‑sen University Cancer Center 
between January 2003 and December 2012 were included in the study. Among these patients, 376 received R‑CHOP 
regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) as primary treatment, and 135 
received CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone) as primary treatment. Intrathe‑
cal chemotherapy prophylaxis (methotrexate plus cytarabine) was administered to those who were deemed at high 
risk for CNS relapse. In the entire cohort and in the R‑CHOP set in particular, the Kaplan–Meier method coupled with 
the log‑rank test was used for univariate analysis, and the Cox proportional hazards model was used for multivariate 
analysis. Differences were evaluated using a two‑tailed test, and P < 0.05 was considered significant.
Results: At a median follow‑up of 46 months, 25 (4.9%) patients experienced CNS relapse. There was a trend of 
reduced occurrence of CNS relapse in patients treated with rituximab; the 3‑year cumulative CNS relapse rates were 
7.1% in CHOP group and 2.7% in R‑CHOP group (P = 0.045). Intrathecal chemotherapy prophylaxis did not confer 
much benefit in terms of preventing CNS relapse. Bone involvement [hazard ratio (HR) = 4.21, 95% confidence 
interval (CI) 1.38–12.77], renal involvement (HR = 3.85, 95% CI 1.05–14.19), alkaline phosphatase (ALP) >110 U/L 
(HR = 3.59, 95% CI 1.25–10.34), serum albumin (ALB) <35 g/L (HR = 3.63, 95% CI 1.25–10.51), treatment with rituxi‑
mab (HR = 0.34, 95% CI 0.12–0.96), and a time to complete remission ≤ 108 days (HR = 0.22, 95% CI 0.06–0.78) were 
independent predictive factors for CNS relapse in the entire cohort. Bone involvement (HR = 4.44, 95% CI 1.08–18.35), 
bone marrow involvement (HR = 11.70, 95% CI 2.24–60.99), and renal involvement (HR = 10.83, 95% CI 2.27–51.65) 
were independent risk factors for CNS relapse in the R‑CHOP set.
Conclusions: In the present study, rituximab decreased the CNS relapse rate of DLBCL, whereas intrathecal chemo‑
therapy prophylaxis alone was not sufficient for preventing CNS relapse. Serum levels of ALB and ALP, and the time to 
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Background
Diffuse large B-cell lymphoma (DLBCL) is the most 
common lymphoid malignancy in adults, comprising 
30%–35% of all non-Hodgkin lymphoma (NHL) cases [1, 
2]. According to recent estimates, patients with DLBCL 
have a 5% overall risk of central nervous system (CNS) 
relapse [3]. Although relatively uncommon, CNS relapse 
is nearly always fatal. This CNS event can dramatically 
shorten the overall survival (OS) of DLBCL patients to 
less than 6 months [4]. Early detection of high-risk cases 
and effective CNS prophylaxis or treatment are the main 
strategies for outcome improvement. Several studies have 
identified high-risk patients to be those with advanced 
stages of disease, elevated lactate dehydrogenase (LDH) 
level, and involvement of multiple extranodal sites or spe-
cific extranodal sites (e.g. the paranasal sinus, breast, tes-
ticle, bone marrow, kidney, orbital and epidural spaces) 
[5, 6]. MYC gene rearrangements was also reported to be 
a risk factor for DLBCL, and treatment regimens simi-
lar to those for Burkitt lymphoma were recommended 
to DLBCL patients [7, 8]. The National Comprehensive 
Cancer Network (NCCN) guideline recommends using 
the international prognostic index (IPI) and measuring 
renal involvement to evaluate the risk of CNS relapse in 
DLBCL patients. However, even knowing the risk fac-
tors and using this screening method, only half of high-
risk patients can be identified [9]. In the era of rituximab, 
high-risk cases should be effectively evaluated for early 
intervention. Whether other risk factors can predict CNS 
relapse remains an open question.
The addition of the chimeric anti-CD20 monoclonal 
antibody rituximab to CHOP regimen (cyclophospha-
mide, doxorubicin, vincristine, and prednisone), termed 
the R-CHOP regimen, has greatly improved the survival 
of DLBCL patients [10–15]. Currently, chemo-immu-
notherapy with R-CHOP regimen or its derivatives is 
the standard first-line therapy for DLBCL [11, 13, 16]. 
Because rituximab can hardly penetrate the blood–brain 
barrier to reach the CNS, its efficacy in preventing CNS 
relapse is still controversial [17]. To cross the blood–
brain barrier and increase therapeutic concentrations 
in the brain and cerebrospinal fluid (CSF), intrathecal 
(IT) administration of methotrexate (MTX) or cytara-
bine (Ara-C) is a simple and well-accepted method for 
CNS prophylaxis. Nonetheless, the benefit of IT chemo-
therapy administration for CNS relapse prophylaxis has 
been questioned in recent years. Certain studies have 
suggested that IT chemotherapy prophylaxis alone is an 
inadequate strategy for the prevention of CNS relapse [4, 
6, 18, 19].
In this study in the post-rituximab era, we aimed to ret-
rospectively explore the risk factors for CNS relapse in an 
entire cohort and in an R-CHOP set in particular and to 
evaluate the efficacy of rituximab and IT chemotherapy 
prophylaxis for CNS relapse reduction.
Methods
Patient selection
Patients with newly diagnosed DLBCL treated at the Sun 
Yat-sen University Cancer Center between January 2003 
and December 2012 were included in this retrospective 
study. All of them had been diagnosed by biopsy accord-
ing to the 2001 or 2008 World Health Organization clas-
sification. The patients in this study were 18  years or 
older and lacked CNS relapse at the time of diagnosis. 
Other selection criteria included receiving anthracy-
cline-based chemotherapy as a first-line treatment with 
curative intent; lacking human immunodeficiency virus 
(HIV) infection; and having adequate clinical informa-
tion available, including follow-up data. The Ann-Arbor 
staging system and the IPI were used for staging evalu-
ation and risk stratification. This study was approved by 
the Institutional Review Board of Sun Yat-sen University 
Cancer Center (Approval No. YB2014-11-20).
Treatment and IT chemotherapy prophylaxis
R-CHOP regimen was recommended to all enrolled 
patients as the standard first-line treatment. However, 
several patients chose chemotherapy without rituximab. 
The entire cohort could be divided into R-CHOP and 
CHOP groups. R-CHOP/CHOP-based regimens with 
minor modifications were also regarded as R-CHOP/
CHOP chemotherapy.
IT chemotherapy prophylaxis was administered to 
those patients who were deemed at high risk of CNS 
relapse at the discretion of the physician. In general, IT 
chemotherapy prophylaxis was performed more often 
in patients with bulky mass; a high level of ki-67; and 
involvement of the testis, breast, or kidney in our cancer 
center. The regimen consisted of 15 mg MTX and 50 mg 
Ara-C administered by lumbar puncture on the first day 
of each cycle. CSF samples from these patients were sent 
complete remission were new independent predictive factors for CNS relapse in the patients with DLBCL. In the patients 
received R‑CHOP regimen, a trend of increased CNS relapse was found to be associated with extranodal lesions.
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for laboratory tests. Diagnosis of CNS relapse was based 
on radiologic evidence, cytological findings, or clinical 
symptoms of CNS relapse.
Follow‑up
The number of first-line chemotherapy cycles and sub-
sequent treatment were decided according to the stage 
of disease, the response to previous treatment, and the 
patients’ characteristics. After treatment, patients were 
followed up every 3 months in the first 3 years and every 
6  months thereafter. During the follow-up period, rou-
tine examinations included physical examination, stand-
ard laboratory tests, echocardiography, and a whole-body 
computed tomography (CT) scan or fluorodeoxyglucose-
positron emission tomography (FDG-PET). Lumbar 
puncture, head CT, or head magnetic resonance imaging 
(MRI) was mainly administered to those with the clini-
cal symptoms of CNS relapse. The final follow-up date in 
this study was May 31, 2015.
Statistical analysis
The clinical characteristics of the entire cohort and the 
patients who experienced CNS relapse in the R-CHOP 
and CHOP sets were compared using the Chi square test 
or Fisher’s exact test.
CNS relapse was the primary endpoint of our study. 
The CNS relapse-free survival rate was calculated from 
the date of initial diagnosis to the date of CNS relapse, 
death without CNS relapse, or last follow-up. The 
Kaplan–Meier method coupled with the log-rank test 
was used for univariate analyses and generation of sur-
vival curves. All factors with P values less than 0.10 were 
included in the multivariate analysis using the Cox pro-
portional hazards model. The secondary endpoints were 
OS and progression-free survival (PFS). OS was defined 
as the time from the date of diagnosis to the date of 
death or last follow-up. PFS was calculated from the date 
of diagnosis to the date of disease progression/relapse, 
death, or last follow-up. The OS and PFS of patients 
with or without CNS relapse were estimated using the 
Kaplan–Meier method and the log-rank test.
The time to complete remission (TTC) was calculated 
from the date of first treatment to the date of first com-
plete remission (CR). Receiver operating characteristic 
(ROC) curve analysis was used to determine the optimal 
cutoff points for the TTC. The TTC was also included in 
the univariate and multivariate analyses. Differences were 
evaluated using a two-tailed test, and P < 0.05 was con-
sidered statistically significant. All statistical analysis was 




A total of 511 patients with DLBCL were included in 
our analysis. Among these patients, 295 (57.7%) were 
men, and 216 (42.3%) were women. The median age was 
52 years old (range, 18–82 years). There were 376 (73.6%) 
patients who received R-CHOP regimen as primary treat-
ment, and the remaining 135 (26.4%) patients received 
CHOP regimen; 217 (42.5%) with advanced-stage (stages 
III and IV) disease; involvement of more than one 
extranodal organ was found in 94 (18.4%) patients, and 
an elevated serum LDH level was found in 214 (41.9%) 
patients. CNS prophylaxis with IT MTX and Ara-C was 
administered in 62 (12.1%) patients; the median number 
of IT chemotherapy prophylaxis cycles was four (range 
1–8). As recommended by the NCCN model for CNS 
relapse, the 16 patients who scored 4–6 were recognized 
as high-risk cases, of whom four received IT chemo-
therapy prophylaxis. At a median follow-up of 46 months 
(range 1–129  months), 25 (4.9%) patients experienced 
CNS relapse; only five among them were in the high-risk 
group based on the NCCN model. The median time to 
CNS relapse among the 25 patients was 7 months (range 
1–46  months). The TTC was calculated in 396 (77.5%) 
patients, who achieved CR at least once. ROC curve anal-
ysis revealed the optimal cutoff value of TTC as 108 days, 
with an area under the curve of 0.64 (Fig.  1). Among 
the patients who achieved CR, 12 received rituximab as 
maintenance therapy. The detailed baseline characteris-
tics of the entire cohort and the CNS relapse cohort are 
displayed in Table 1. There was no significant difference 
in clinical characteristics between the R-CHOP and the 
CHOP sets in the two cohorts, except for a difference in 
the TTC. Compared with the CHOP set, more patients 
in the R-CHOP set achieved a rapid CR in both cohorts.
CNS relapse and its risk factors in the entire cohort
A total of 11 (8.1%) patients in the CHOP set and 14 
(3.7%) in the R-CHOP set developed CNS relapse within 
the follow-up period (P = 0.041); the median time to CNS 
relapse was 7  months in the CHOP set and 6.5  months 
in the R-CHOP set. Comparing the two sets, there was 
a trend of a reduced likelihood of CNS relapse in the 
R-CHOP set: the 3-year CNS relapse rate was 2.7% in the 
R-CHOP set and 7.1% in the CHOP set (P = 0.045). Uni-
variate analysis of the effect of rituximab maintenance 
on CNS relapse in patients with CR showed a P value of 
0.997, implying that rituximab maintenance could not 
decrease the occurrence of CNS relapse. Among patients 
treated with IT chemotherapy prophylaxis, 6 (9.7%) expe-
rienced CNS relapse, whereas 19 (4.2%) among those 
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without IT chemotherapy prophylaxis experienced CNS 
relapse. The addition of IT chemotherapy prophylaxis 
did not confer much benefit for CNS relapse: the 3-year 
CNS relapse rates in patients with and without IT were 
6.5% and 2.0% (P = 0.062). In the high-risk group, as rec-
ognized by the NCCN model, univariate analysis of the 
effect of IT chemotherapy prophylaxis on CNS relapse 
showed a P value of 0.171. Therefore, in this small group 
of high-risk patients, IT chemotherapy prophylaxis also 
showed no benefit in reducing CNS relapse. Patients who 
experienced CNS relapse were less likely to achieve a 
rapid CR than those who did not experience CNS relapse 
(28.0% vs. 52.3%, P = 0.023); patients who achieved their 
first CR within 108 days had a trend towards a lower risk 
of CNS relapse than those who failed to reach CR within 
108 days (1.1% vs. 7.7%, P < 0.001).
Univariate analysis of the entire cohort detected that 
the increased risk of CNS relapse was associated with 
advanced-stage (stage III or IV) disease, an IPI ≥3, 
involvement of more than one extranodal site, involve-
ment of the bone marrow, involvement of the bone, 
involvement of the kidney, an absolute lymphocyte count 
<1.3  ×  109/L, elevated serum LDH level (>245  U/L), 
elevated alkaline phosphatase (ALP) level (>110  U/L), 
reduced serum albumin (ALB) level (<35  g/L), reduced 
high-density lipoprotein (HDL) level (<0.78  mmol/L), 
reduced serum apolipoprotein-A1 (Apo-A1) level 
(<1.05  g/L), lack of rituximab treatment, failure to 
attain CR after first-line therapy, and a TTC >108  days 
(all P  <  0.05). Additional risk factors with P values 
less than 0.10 were also identified: an absolute white 
blood cell (WBC) count <4.0  ×  109/L, a platelet count 
≥100  ×  109/L, serum total protein (TP) <60  g/L, and 
receipt of IT chemotherapy prophylaxis. The results of 
the univariate analysis are listed in Table 2, and the CNS 
relapse-free survival curves of patients with independent 
risk factors can be observed in Fig. 2.
In the multivariate Cox regression analysis, bone involve-
ment, renal involvement, ALP, ALB, treatment with rituxi-
mab, and the TTC were independently predictive of CNS 
relapse (Table 3).
CNS relapse and its risk factors in the R‑CHOP set
To evaluate the risk factors for CNS relapse among 
patients treated with R-CHOP regimen, univariate and 
multivariate analyses of the R-CHOP set were performed. 
IT chemotherapy prophylaxis still showed no protec-
tive effect against CNS relapse: the numbers of patients 
who experienced CNS relapse in the groups treated with 
and without IT chemotherapy prophylaxis were 4 (8.5%) 
and 11 (3.3%), and the 3-year CNS relapse rates in the 
IT chemotherapy prophylaxis and non-IT prophylaxis 
groups were 6.4% and 1.8% (P =  0.104). A longer TTC 
was no longer associated with an increased risk of CNS 
relapse. In both the univariate and the multivariate analy-
ses, fewer factors were found to be significantly predic-
tive of CNS relapse in the individual groups than in the 
entire cohort. Univariate analysis showed that advanced-
stage disease, an IPI ≥3, involvement of more than one 
extranodal site, involvement of the bone marrow, bone, 
kidney, or testicle, an elevated ALP level (>110 U/L), and 
reduced HDL level (<0.78 mmol/L) were significant risk 
factors. Other factors with P values less than 0.10 were an 
absolute lymphocyte count <1.3 ×  109/L and treatment 
with IT chemotherapy prophylaxis. Details are listed in 
Table  4, and the survival curves with independent risk 
factors can be observed in Fig. 3.
In the multivariate analysis, involvement of the bone, 
bone marrow, and kidney were independent predictive 
factors for CNS relapse (Table 5).
OS and PFS of patients
The outcomes of patients with CNS relapse were much 
worse than those of patients without CNS relapse. The 
median OS and PFS were 16.0 and 7.3  months for the 
whole cohort. The 5-year OS rates in patients with or 
without CNS relapse were 13.3% and 74.6% (P < 0.001); 
the 5-year PFS rates in patients with or without CNS 
relapse were 0 and 69.7% (P < 0.001). Seventeen (68.0%) 
of the 25 patients who experienced CNS relapse died, 
and the median survival after CNS relapse was 8 months 
(range 4–16 months). The OS and PFS curves can be vis-
ualized in Fig. 4.
Fig. 1 Receiver operating characteristic (ROC) curve analysis 
detected the cutoff point of time to complete remission (TTC) as 
108 days. AUC area under curve
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Table 1 Characteristics of  the 511 diffuse large B-cell lymphoma (DLBCL) patients in  the entire cohort and  the central 
nervous system (CNS) relapse cohort (CHOP vs. R-CHOP)
Clinical factor Entire cohort [cases (%)] CNS relapse cohort [cases (%)]
CHOP R‑CHOP P CHOP R‑CHOP P
Total 135 376 11 14
Age 0.563 1.000
 ≤60 years 98 (72.6) 263 (69.9) 8 (72.7) 10 (71.4)
 >60 years 37 (27.4) 113 (30.1) 3 (27.3) 4 (28.6)
Gender 0.694 0.115
 Male 76 (56.3) 219 (58.2) 5 (45.5) 11 (78.6)
 Female 59 (43.7) 157 (41.8) 6 (54.5) 3 (21.4)
Stage 0.892 0.434
 I or II 77 (57.0) 217 (57.7) 5 (45.5) 4 (28.6)
 III or IV 58 (43.0) 159 (42.3) 6 (54.5) 10 (71.4)
B symptoms 0.663 1.000
 No 95 (70.4) 272 (72.3) 7 (63.6) 8 (57.1)
 Yes 40 (29.6) 104 (27.7) 4 (36.4) 6 (42.9)
Bulky diseasea,b 0.238 0.500
 No 91 (67.4) 252 (67.0) 6 (54.5) 8 (57.1)
 Yes 10 (7.4) 17 (4.5) 0 (0) 2 (14.3)
Involved extranodal sitesc 0.617 0.414
 ≤1 112 (83.0) 303 (80.6) 8 (72.7) 7 (50)
 >1 23 (17.0) 71 (18.9) 3 (27.3) 7 (50)
Sinus involvement 0.971 0.604
 No 119 (88.1) 331 (88.0) 10 (90.9) 11 (78.6)
 Yes 16 (11.9) 45 (12.0) 1 (9.1) 3 (21.4)
Bone involvement 0.947 0.407
 No 120 (88.9) 335 (89.1) 9 (81.8) 9 (64.3)
 Yes 15 (11.1) 41 (10.9) 2 (18.2) 5 (35.7)
Bone marrow involvement 0.177 0.230
 No 133 (98.5) 360 (95.7) 11 (100) 11 (78.6)
 Yes 2 (1.5) 16 (4.3) 0 (0) 3 (21.4)
Liver involvement 0.792 0.487
 No 131 (97.0) 361 (96.0) 11 (100) 12 (85.7)
 Yes 4 (3.0) 15 (4.0) 0 (0) 2 (14.3)
Testicular involvement 0.526 1.000
 No 131 (97.0) 368 (97.9) 11 (100) 13 (92.9)
 Yes 4 (3.0) 8 (2.1) 0 (0) 1 (7.1)
Renal involvement 0.782 0.661
 No 130 (96.3) 360 (95.7) 9 (81.8) 10 (71.4)
 Yes 5 (3.7) 16 (4.3) 2 (18.2) 4 (28.6)
Breast involvement 0.318 –
 No 130 (96.3) 368 (97.9) 11 (100) 14 (100)
 Yes 5 (3.7) 8 (2.1) 0 (0) 0 (0)
Female genital tract involvement 0.063 –
 No 131 (97.0) 373 (99.2) 11 (100) 14 (100)
 Yes 4 (3.0) 3 (0.8) 0 (0) 0 (0)
IPI 0.096 0.208
 0–2 113 (83.7) 289 (76.9) 9 (81.8) 7 (50.0)
 3–5 22 (16.3) 87 (23.1) 2 (18.2) 7 (50.0)
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Discussion
In this retrospective study of 511 newly diagnosed 
DLBCL cases, we demonstrated the effect of rituximab 
and found the current IT prophylactic strategy to be 
insufficient in decreasing the incidence of CNS relapse. 
We also established three new independent risk factors 
for CNS relapse: ALB level, ALP level, and the TTC. The 
impact of the TTC on CNS relapse indicated that the 
response to treatment could also be a risk factor for pre-
dicting CNS relapse in addition to the clinical character-
istics at diagnosis. In the R-CHOP set, the involvement of 
certain specific extranodal sites (the bone, bone marrow, 
and kidney) as independent risk factors showed a ten-
dency to increase CNS relapse risk.
Several studies have reported the impact of rituximab 
on reducing CNS relapse. In the “rituximab with CHOP 
over age 60  years” (RICOVER-60) trial, 1222 elderly 
patients with aggressive B-cell lymphoma were treated 
with six or eight cycles of CHOP regimen every 2 weeks 
with or without rituximab [20]. The 2-year CNS relapse 
rate was significantly lower in the R-CHOP group than in 
the CHOP group (4.1% vs. 6.9%, P = 0.043). Nonetheless, 
the patients in this prospective study did not all have 
DLBCL; other B-cell lymphomas comprised approxi-
mately 18.4% of cases. Shimazu et  al. [21] examined 
403 patients with DLBCL and found a trend of reduced 
occurrence of CNS relapse in patients treated with rituxi-
mab. However, several other studies reached different 
conclusions. In the Groupe d’Etude des Lymphomes de 
l’Adulte (GEAL) trial of 399 elderly lymphoma patients 
treated with 8 cycles of R-CHOP or CHOP regimen, add-
ing rituximab showed no influence on CNS relapse [22]. 
This difference may be due to the varying patient char-
acteristics in each study. In our study, rituximab treat-
ment was found to be an independent risk factor for CNS 
relapse. Although the penetration of rituximab through 
the blood–brain barrier is extremely poor, it may still 
reduce CNS relapse by better systemic control of the dis-
ease [19].
As a simple approach to CNS prophylaxis, IT chemo-
therapy is usually administered to high-risk patients 
with involvement of specific extranodal sites. Recently 
published data suggest that CNS prophylaxis alone may 
not be effective in reducing CNS relapse. In the 20-year 
Table 1 continued
Clinical factor Entire cohort [cases (%)] CNS relapse cohort [cases (%)]
CHOP R‑CHOP P CHOP R‑CHOP P
LDHd 0.768 0.677
 ≤1 ULNe 79 (58.5) 215 (57.2) 3 (27.3) 6 (42.9)
 >1 ULN 55 (40.7) 159 (42.3) 8 (72.7) 8 (57.1)
ALB 0.464 0.656
 <35 g/L 114 (84.4) 327 (87.0) 4 (36.4) 3 (21.4)
 ≥35 g/L 21 (15.6) 49 (13.0) 7 (63.6) 11 (78.6)
ALPf 0.529 1.000
 ≤110 U/L 119 (88.1) 341 (90.7) 8 (72.7) 10 (71.4)
 >110 U/L 15 (11.1) 35 (9.3) 3 (27.3) 4 (28.6)
IT chemotherapy prophylaxisg 0.640 0.661
 No 117 (86.7) 329 (87.5) 9 (81.8) 10 (71.4)
 Yes 18 (13.3) 44 (11.7) 2 (18.2) 4 (28.6)
TTCh 0.016 0.003
 ≤108 days 54 (40.0) 207 (55.1) 0 (0) 7 (50.0)
 >108 days 67 (49.6) 155 (41.2) 10 (90.9) 3 (21.4)
CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone, R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, IPI international 
prognostic index, LDH lactate dehydrogenase, ULN upper limit of normal, ALB albumin, ALP alkaline phosphatase, IT intrathecal, TTC time to complete remission
a Bulky disease: mass ≥7.5 cm
b In the entire cohort, the data of 34 patients in the CHOP group and seven patients in the R-CHOP group were missing; in the CNS relapse cohort, the data of five 
patients in the CHOP group and four patients in the R-CHOP group were missing
c In the entire cohort, the data of two patients in the R-CHOP group were missing
d In the entire cohort, the data of one patient in the CHOP group and two patients in the R-CHOP group were missing
f In the entire cohort, the data of one patient in the CHOP group were missing
g In the entire cohort, the data of three patients in the R-CHOP group were missing
h In the entire cohort, the data of 14 patients in the CHOP group and 14 patients in the R-CHOP group were missing; in the CNS relapse cohort, the data of one patient 
in the CHOP group and four patients in the R-CHOP group were missing
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follow-up analysis by the Southwest Oncology Group 
(SWOG) [20], 899 patients with aggressive lymphoma 
were enrolled, 34 of whom had bone marrow involve-
ment and received at least one dose of IT therapy. The 
study showed no significant benefit in the prevention of 
CNS relapse in patients who received IT chemotherapy 
prophylaxis [23]. A study by Tomita et al. [24] retrospec-
tively analyzed the data of 322 patients who achieved 
their first CR after R-CHOP therapy and concluded that 
IT administration of MTX was insufficient to prevent 
CNS relapse. Consistent with these studies, we did not 
find a significantly protective effect of IT administra-
tion against CNS relapse in either the entire cohort or 
the R-CHOP set. For the patients with high risk of CNS 
relapse identified either at the discretion of the physi-
cian in our hospital or according to the NCCN model, IT 
chemotherapy prophylaxis showed no significant effect 
Table 2 Univariate analysis of risk factors for CNS relapse 
in the entire cohort




 I or II 294 9 (3.1)
 III or IV 217 16 (7.4)
IPI 0.026
 0–2 402 16 (4.0)
 3–5 109 9 (8.3)
Number of involved 
extranodal sitesa
0.001
 ≤1 415 15 (3.6)




 No 493 22 (4.5)
 Yes 18 3 (16.7)
Bone involvement 0.001
 No 455 18 (4.0)
 Yes 56 7 (12.5)
Renal involvement <0.001
 No 490 19 (3.9)
 Yes 21 6 (28.6)
WBC countb 0.056
 <4.0 × 109/L 32 4 (12.5)
 ≥4.0 × 109/L 478 21 (4.4)
LCc 0.027
 <1.3 × 109/L 169 12 (7.1)
 ≥1.3 × 109/L 341 13 (3.8)
PLTd 0.063
 <100 × 109/L 21 2 (9.5)
 ≥100 × 109/L 489 23 (4.7)
LDHe 0.015
 ≤1 ULNf 294 9 (3.1)
 >1 ULN 214 16 (7.5)
ALPg 0.001
 ≤110 U/L 460 18 (3.9)
 >110 U/L 50 7 (14.0)
ALB 0.005
 <35 g/L 441 7 (1.6)
 ≥35 g/L 70 18 (25.7)
TP 0.063
 < 60 g/L 56 7 (12.5)
 ≥60 g/L 455 18 (4.0)
HDLh 0.014
 < 0.78 mmol/L 94 10 (10.6)
 ≥0.78 mmol/L 409 14 (3.4)
Apo‑A1i 0.030
 <1.05 g/L 205 14 (6.8)
 ≥1.05 g/L 296 9 (3.0)
Table 2 continued




 Without 135 11 (8.1)




 No 446 19 (4.3)
 Yes 62 6 (9.7)
CR with first‑line 
therapyk
0.036
 No 157 14 (8.9)
 Yes 349 11 (3.1)
TTCl 0.003
 ≤108 days 261 7 (2.6)
 >108 days 222 13 (5.9)
WBC white blood cell, LC lymphocyte count, PLT platelet count, TP total 
protein, HDL high-density lipoprotein, Apo-A1 apolipoprotein-A1, CR complete 
remission. Other abbreviations as in Table 1
a The data of two patients were missing
b The data of one patient were missing
c The data of one patient were missing
d The data of one patient were missing
e The data of three patients were missing
f ULN for LDH: 245 U/L
g The data of one patient were missing
h The data of eight patients, including one who developed in the CNS relapse, 
were missing
i The data of ten patients, including two who developed CNS relapse, were 
missing
j The data of three patients were missing
k The data of five patients were missing
l The data of 28 patients, including five patients who developed CNS relapse, 
were missing
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on preventing CNS relapse. The limited impact of IT 
chemotherapy prophylaxis on CNS relapse was consist-
ent with the understanding that it is difficult to achieve 
therapeutic levels of MTX and Ara-C in the brain paren-
chyma via this route of administration [3]. A systemic 
treatment with high-dose MTX may be necessary in 
patients with high-risk features [25].
Renal involvement is uncommon in DLBCL patients. 
Certain studies have described patients with renal 
involvement as having a poor outcome due to a high rate 
of CNS relapse. Villa et al. [26] reported a retrospective 
study of 2656 DLBCL patients, among whom 52 patients 
had renal involvement at diagnosis. Of the 52 patients, 20 
(36%) developed CNS relapse shortly after diagnosis and 
treatment, with a median time to relapse of 5.6 months. 
In our study, renal involvement was a significant risk fac-
tor for CNS relapse in univariate and multivariate analy-
ses of both the entire cohort and the R-CHOP set.
Bone and bone marrow involvement has also been 
noted to carry a high risk of CNS relapse. Tomita et  al. 
[27] examined 1221 patients with DLBCL who received 
R-CHOP regimen as primary therapy and noted the 
cumulative 5-year probability of CNS relapse to be 8.4%. 
Bone involvement [relative risk (RR) = 2.0, 95% CI 1.1–
4.0] was found to be an independent risk factor for CNS 
relapse. Regarding bone marrow involvement, Shimazu 
et al. [21] reported a study of 403 patients with DLBCL, 
Fig. 2 Kaplan–Meier analysis estimated central nervous system (CNS) relapse‑free survival for the 511 diffuse large B‑cell lymphoma (DLBCL) 
patients stratified by independent risk factors. A low albumin (ALB) level at diagnosis (a), a high alkaline phosphatase (ALP) level (b), bone involve‑
ment (c), renal involvement (d), a lack of rituximab treatment (e), and a long time to complete remission (TTC) (f) were associated with short CNS 
relapse‑free survival
Table 3 Multivariate analysis of  risk factors for  CNS 
relapse in the entire cohort
HR hazard ratio, CI confidence interval. Other abbreviations as in Table 1
Variable HR 95% CI P
Bone involvement 4.21 1.38–12.77 0.011
Kidney involvement 3.85 1.05–14.19 0.043
ALP > 110U/L 3.59 1.25–10.34 0.018
ALB < 35g/L 3.63 1.25–10.51 0.018
Rituximab treatment 0.34 0.12–0.96 0.042
TTC ≤ 108 days 0.22 0.06–0.78 0.019
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and the multivariate analysis identified bone marrow 
involvement (RR  =  2.099, 95% CI 1.049–4.200) as an 
independent predictor of CNS relapse. Our study found 
that bone involvement carried a relatively high risk of 
CNS relapse in both the entire cohort and the R-CHOP 
set.
Certain studies have provided evidence that testicular 
lymphoma is associated with a high rate of CNS relapse. 
Guirguis et  al. [28] reported a retrospective study of 
214 DLBCL patients and found that testicular involve-
ment was the only significant prognostic factor for 
CNS relapse. Park et  al. [29] performed an analysis of 
45 patients with primary testicular lymphoma, among 
whom 20% experienced CNS relapse, with a median 
follow-up duration of 31.6  months. Many hospitals as 
well as our cancer center routinely administer IT chem-
otherapy to patients with testicular involvement. How-
ever, testicular involvement was a high risk factor only in 
the univariate analysis of the R-CHOP set in our study. 
As testicular involvement was only detected in 12 of 511 
patients, this result may be attributable to the small num-
ber of specific patients.
Hollender et al. [30] built a risk model for CNS relapse 
in patients with NHL. A total of 2514 patients were 
enrolled, and 1220 were found to have high-grade histol-
ogy. Among these high-grade B-cell and T-cell lymphoma 
patients, five independent risk factors for CNS relapse 
were identified: elevated LDH level, serum ALB <35 g/L, 
<60  years of age, retroperitoneal lymph node involve-
ment, and involvement of more than one extranodal site. 
Serum ALB <35 g/L was also reported as a risk factor in 
the risk model for CNS relapse of high-grade lymphoma. 
In our study of the entire cohort, the patients with ALB 
<35  g/L (HR =  3.63, 95% CI 1.25–10.51) showed a rel-
atively high risk for CNS relapse, and ALB <35 g/L was 
identified as an independent risk factor. This finding sug-
gests that serum ALB level is a risk factor for CNS relapse 
when the analysis is restricted to DLBCL patients. ALP 
is a type of plasma membrane-bound glycoprotein that 
is widely distributed in human tissue, and its elevation 
in the serum indicates the presence of involvement of 
the bone, liver, and other sites [31]. In our study, elevated 
ALP level (HR = 3.59, 95% CI 1.25–10.34) was found to 
increase the rate of CNS relapse in the univariate and 
multivariate analyses. The mechanism of this risk factor 
should be further explored.
In our study, the DLBCL patients who failed to achieve 
CR quickly had a high risk of CNS relapse. Considering 
this finding, salvage chemotherapy of CNS prophylaxis 
may be necessary for patients with late CR and for those 
who fail to achieve CR. Compared with the entire cohort, 
there were fewer risk factors for CNS relapse in the 
Table 4 Univariate analysis of risk factors for CNS relapse 
in the R-CHOP set
Abbreviations as in Table 1
a The data of two patients were missing
b The data of five patients were missing
c The data of three patients were missing




 I or II 217 4 (1.8)
 III or IV 159 10 (6.3)
IPI 0.017
 0–2 289 7 (2.4)
 3–5 87 7 (8.0)
Number of involved 
extranodal sitesa
0.004
 ≤1 303 7 (2.3)




 No 360 11 (3.1)
 Yes 16 3 (18.8)
Bone involvement 0.001
 No 335 9 (2.7)
 Yes 41 5 (12.2)
Renal involvement <0.001
 No 360 10 (2.8)
 Yes 16 4 (25.0)
Testicular involvement 0.043
 No 368 13 (3.5)
 Yes 8 1 (12.5)
LC 0.081
 <1.3 × 109 132 12 (9.1)
 ≥1.3 × 109 244 2 (0.8)
ALP 0.019
 ≤110 U/L 341 10 (2.9)
 >110 U/L 35 4 (11.4)
HDLb 0.028
 <0.78 mmol/L 64 10 (15.6)




 No 329 10 (3.0)
 Yes 44 4 (9.1)
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R-CHOP set. The use of rituximab may decrease the risk 
level of many risk factors for CNS relapse. Among those 
treated with R-CHOP regimen, efforts to counteract CNS 
relapse should be focused on patients with involvement 
of specific extranodal sites.
In conclusion, CNS relapse is an uncommon but fatal 
event in DLBCL patients. Rituximab appears to decrease 
the rate of CNS relapse, and the effect of IT chemother-
apy prophylaxis seems limited. ALB level, ALP level, and 
the TTC are new risk factors for predicting CNS relapse. 
In patients treated with R-CHOP regimen, there is a 
trend of increased risk for those with involvement of spe-
cific extranodal sites, such as the kidney, bone, and bone 
marrow. For patients with a high risk of CNS relapse, 
prophylactic strategies, such as systemic high-dose MTX, 
should be recommended.
Fig. 3 Kaplan–Meier analysis estimated CNS relapse‑free survival for the 376 patients in the R‑CHOP (rituximab, cyclophosphamide, doxorubicin, 
vincristine, and prednisone) set stratified by independent risk factors. Renal involvement (a), bone involvement (b), and bone marrow (BM) involve‑
ment (c) were associated with short CNS relapse‑free survival
Table 5 Multivariate analysis of  risk factors for  CNS 
relapse in the R-CHOP set
Abbreviations as in Tables 1 and 3
Variable HR 95% CI P
Bone involvement 5.04 1.20–21.24 0.028
Bone marrow involvement 12.63 2.39–66.74 0.003
Renal involvement 7.24 1.50–34.95 0.014
Fig. 4 Kaplan–Meier analysis estimated overall survival (OS) and progression‑free survival (PFS) for 511 DLBCL patients with or without CNS relapse. 
CNS relapse was associated with short OS (a) and short PFS (b)
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